ImmunoGen Message Board - Msg: 31173513

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunoGen

IMGN 31.23

0.0%

Feb 26 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: Gary Mohilner	7/6/2017 7:56:32 PM
	of 5665

I believe their is a growing awareness that IMGN's technology is producing superior results to what's coming out of SGEN. While their market caps are dramatically different, I believe money is coming out of SGEN and into IMGN and will continue to do so until either the two are more equal, or SGEN does have another drug approved. As things stand, Bayer's drug should complete it's registrational Phase 2 Trial this year, that would make it the second drug using IMGN's technology to be approved when it's approved next year. IMGN853 should be the first wholly owned drug to be approved, probably not until 2020, but possibly sooner. By the time this occurs, I believe IMGN's market cap will be no less than $5 billion, perhaps it will equal the roughly $9 billion SGEN achieved earlier this year. I believe IMGN's price by end of this year will be in the $15 to $25 range, that should once again put it somewhere between a quarter and half of SGEN's market cap. Of course it's possible that SGEN will gain some positive news for another drug advancing in trials, but at this time I believe what's known favors IMGN. Gary

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next